Antiobesity Pharmacotherapy for Patients with Type 2 Diabetes: Focus on Long-Term Management.
10.3803/EnM.2014.29.4.410
- Author:
Won Seon JEON
1
;
Cheol Young PARK
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. cydoctor68@gmail.com
- Publication Type:Review
- Keywords:
Obesity;
Drug therapy;
Diabetes
- MeSH:
Bariatric Surgery;
Drug Therapy*;
Energy Intake;
Humans;
Hypoglycemic Agents;
Insulin;
Insulin Resistance;
Obesity;
United States Food and Drug Administration;
Weight Gain;
Liraglutide
- From:Endocrinology and Metabolism
2014;29(4):410-417
- CountryRepublic of Korea
- Language:English
-
Abstract:
Type 2 diabetes and obesity have a complex relationship; obesity is linked to insulin resistance, the precursor to type 2 diabetes. The management of obesity is an important method to delay onset of diabetes and improve the glycemic durability of antidiabetic agents. However, insulin and some of the oral hypoglycemic agents used to treat diabetes cause significant weight gain, and it is difficult for patients with diabetes to reduce and maintain their weight by life-style changes alone. Thus, antiobesity medications or bariatric surgery may be a necessary adjunct for certain obese patients with diabetes. In 2012, the U.S. Food and Drug Administration (FDA) approved lorcaserin and phentermine/topiramate extended-release for the management of chronic weight, and approval for naltrexone/bupropion sustained-release as an adjunct to exercise and reduced caloric intake followed in 2014. Liraglutide is pending FDA approval for antiobesity drug. Here we review the efficacy of approved and new promising drugs for the management of obesity.
